
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Fadi Haddad, MD, discusses updates on the treatment of chronic myeloid leukemia failing frontline therapy.
Fadi Haddad, MD, discusses updates on the treatment of chronic myeloid leukemia failing frontline therapy.






